GVOKE HYPOPEN
Peakglucagon injection, solution
NDASUBCUTANEOUSSOLUTION
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
GVOKE HYPOPEN (glucagon injection, solution) is 12. First approved in 2019.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GVOKE HYPOPEN is a ready-to-use glucagon injection solution for emergency treatment of severe hypoglycemia in patients with diabetes. It works by activating hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver, rapidly raising blood glucose levels. The product is administered subcutaneously and is designed for quick, accessible emergency use by patients or caregivers.
Peak9.5 years to LOE
Product is at peak commercial maturity with ~9.6 years of exclusivity remaining; commercial teams are focused on market penetration and brand loyalty maintenance.
Mechanism of Action
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.